- Advisory Team
- Management Team
- Support Team
Dr. Anderson is the Chief Academic Officer and Senior VP of Research at Brigham and Women’s Hospital. He also serves as the K. Frank Austen Professor of Medicine at Harvard Medical School and the associate chief of the Division of Rheumatology, Immunology and Allergy at Brigham and Women’s Hospital. He is a member of the American Society for Clinical Investigation and the Association of American Physicians and serves on the Scientific Advisory Committee at the American College of Rheumatology.
Before graduating from the medical scientist training program at the New York University School of Medicine, Anderson trained with Jan Vilcek, MD, PhD, the inventor of Remicaid, the first biologic therapy for patients with autoimmune disease. Anderson then came to the Brigham where he completed an internship and residency in Internal Medicine and a fellowship in Rheumatology. In 1990 he started his own research laboratory at BWH focusing on the role that post-transcriptional control of gene expression plays in the regulation of inflammatory and stress response programs. His laboratory has been funded by the NIH and by various foundations and industry collaborations, and has hosted more than 30 MD and/or PhD research fellows. He has authored or co-authored more than 175 publications and is on the editorial boards of a number of journals, including Cellular Immunology and Modern Rheumatology.
In addition, Anderson is a senior physician at BWH and sees patients in the Brigham Arthritis Center ambulatory clinic and attends on the Rheumatology Consult Service.
He is a member of the Rheumatology Division Fellowship Selection Committee, which interviews all applicants for the Rheumatology Fellowship Program and makes recommendations for ranking these candidates.
Anderson received a BS in Biology from SUNY Stony Brook, and received both MD and PhD (Microbiology) from New York University School of Medicine.
Lindsey Baden, MMSc, MD is the Director of Clinical Research in the Division of Infectious Diseases at the Brigham and Women’s Hospital, as well as the Director of Infectious Diseases at the Dana-Farber Cancer Institute.
He is also the Director of the Clinical Center of Investigation (CCI) at BWH. As the Medical Director of the Translational Accelerator, he is integral in the clinical operations.
Dr. Bertagnolli is the Richard E. Wilson Professor of Surgery at Harvard Medical School. She is the Chief of the Division of Surgical Oncology at Dana Farber/Brigham and Women’s Cancer Center (DF/BWCC). She is also a member of the Gastrointestinal Cancer and Sarcoma Disease Centers at DF/BWCC.
From a press release covering her 2018 appointment as president of the American Society for Clinical Oncology (ASCO):
Bertagnolli, a superb clinician and scientist, works closely with colleagues in medical oncology, radiation oncology and pathology to treat patients with incredibly rare and complex diseases, including the treatment of tumors from a gastrointestinal disease that has genetic links to colon cancer.
Bertagnolli is also highly regarded for her leadership and skill in the lab, working with researchers and clinicians on preventing cancer of the colon and has greatly influenced the development of important drug therapies that tens of thousands of people take to prevent colon cancer.
For 15 years, Bertagnolli led gastrointestinal correlative science initiatives within the NCI-funded Cancer Cooperative Groups, where she facilitated integration of tumor-specific molecular markers of treatment outcome into nation-wide clinical cancer treatment protocols. She has also held numerous leadership roles in multi-institutional cancer clinical research consortia, including serving as the group chair of the Alliance for Clinical Trials in Oncology, an NCI-funded cooperative group. She is the chief executive officer of Alliance Foundation Trials, LLC, a not-for-profit corporation that conducts international cancer clinical trials, and a current member of the Foundation for the NIH Biomarkers Consortium, as well as serving on the National Cancer Policy Forum of the Institute of Medicine of the National Academies of Science.
Elazer R. Edelman, M.D., Ph.D., is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at MIT, Professor of Medicine at Harvard Medical School, and Senior Attending Physician in the coronary care unit at the Brigham and Women’s Hospital in Boston. He and his laboratory have pioneered basic findings in vascular biology and the development and assessment of biotechnology. Dr. Edelman directs the Harvard-MIT Biomedical Engineering Center (BMEC), dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease. BMEC programs span a wide range of disciplines, with its resources made available to investigators from MIT and Harvard.
Dr. Edelman received Bachelor of Science degrees in Bioelectrical Engineering and in Applied Biology from MIT, a Masters of Science degree in Electrical Engineering and Computer Sciences from MIT, a Ph.D. in Medical Engineering and Medical Physics from MIT, and an M.D. degree from Harvard Medical School. His graduate thesis work, under the direction of Prof. Robert Langer, defined the mathematics of regulated and controlled drug delivery systems. After internal medicine training and clinical fellowship in Cardiovascular Medicine at the BWH he spent six years as a research fellow in the Department of Pathology at Harvard Medical School with Prof. Morris J. Karnovsky working on the biology of vascular repair.
His research melds his clinical and medical training and interests, focusing on understanding how tissue architecture and biochemical regulation contribute to local growth control. Edelman and his students were among the first to validate that proliferative vascular diseases are the sum of effects from endogenous growth promoters and suppressors. Their characterization of how heparin-like compounds serve as suppressors and heparin-binding growth factors as promoters contributed to the creation of a rigorous framework by which to appreciate how these agents interact with one another in-vivo. Additional studies enabled further definition of the nomenclature and kinetics for the FGF-2 receptor complex, characterization of synergy between many growth factors, and demonstration that the mode of growth factor or inhibitor delivery determines biologic effect. This work and advanced studies of endothelial cell and vascular biology led to the discovery the mutable dynamic of vascular endothelial state and its importance in tissue paracrine and angiocrine regulation in vascular diseases and now cancer.
The applied aspects of their work flow from the umbrella of growth modulation. The Edelman laboratory reasoned that the optimal way to control a biologic event was by recapitulating natural means of regulation. Hence, polymeric controlled drug delivery systems should mimic natural release systems, and vascular implants should be devised with an intimate knowledge of the injury they induce. The development and mathematical characterization of perivascular and stent-based drug delivery is an example of the former, and design of an endovascular and drug-eluting stents from first principles and therapeutic tissue engineered endothelial cell constructs are examples of the latter. Harnessing materials science and emerging imaging modalities they discovered how to track the fate and function of environmentally-responsive dynamic materials in both in vivo and in vitro domains in a correlative fashion for range of materials in different organs, disease states and applications.
Many of his findings are now in clinical trial validation. Almost 300 students and postdoctoral fellows have passed through Dr. Edelman’s laboratory enabling publications of numerous papers and patents.
Elazer is fellow of the American College of Cardiology, American Heart Association, Association of University Cardiologists, American Society of Clinical Investigation, American Institute of Medical and Biological Engineering, and the American Academy of Arts and Sciences, National Academy of Inventors, National Academy of Medicine and National Academy of Engineering. As Chief Scientific Advisor of Science: Translational Medicine he has set the tone for the national debate on translational research and innovation. As co-founder of ASTM F04.03 he helped create standards for cardiovascular implants. He served as a member of FDA’s Science Board and an ORISE fellow in the FDA EIR. For his work bringing cardiovascular translational research to an international level of excellence the Spanish Parliament and King Juan Carlos awarded Elazer with the Spanish Order of Civil Merit for his work. Most importantly as an avid ice hockey goalie Dr. Edelman’s most recent accomplishment involves passing three levels of coaching licensure from the Massachusetts Youth Hockey league and coaching the Brookline Bantam B team.
Dr. Gandhi joined the Ann Romney Center for Neurologic Diseases, in 2004 as a fellow and was promoted to Instructor in 2008. She was appointed as Assistant Professor in Neurology at Harvard in 2012. In the last ten years at Brigham and Women’s Hospital, Dr. Gandhi initiated several research projects related to basic immunology, autoimmune diseases and neurological disorders. Her research is focused on understanding the mechanism of cellular immunity; particularly, induction and characterization of regulatory immune cells and identification of a biomarker for MS. She has identified several circulating miRNAs, which have the potential to serve a role of MS biomarker. The major research focus of her lab includes:
Dr. Elliot Israel is the director of the Respiratory Therapy Department, the director of clinical research in the Pulmonary and Critical Care Medicine Division and an associate physician at Brigham and Women’s Hospital (BWH). He is also a professor of medicine at Harvard Medical School.
He received his medical degree from the Johns Hopkins University School of Medicine. He then completed residency programs in internal medicine at Johns Hopkins Hospital and Weill Cornell Medical Center at New York-Presbyterian Hospital (formerly New York Hospital). He also completed fellowships in pulmonary disease and allergy and immunology at BWH. He is board certified in allergy and immunology, critical care medicine, internal medicine and pulmonary medicine.
Dr. Israel’s research interests include therapeutic interventions to alter asthmatic airway hyperactivity and the role of arachidonic acid metabolites in airway narrowing. He has written over 120 peer-reviewed publications and currently leads a team researching novel asthma treatments funded by the National Institutes of Health. He is the recipient of the HMS Daniel D. Federman Outstanding Clinical Educator Award and was named one of “Boston’s best in Pulmonary Medicine” by Boston Magazine.
Daphne A. Haas-Kogan, MD, is chair of the Department of Radiation Oncology at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC). A professor at Harvard Medical School, she is also be the Endowed Professor of Radiation Oncology at Brigham and Women’s Health Care. In this role, Haas-Kogan is responsible for formulating and directing the educational, research and clinical activities of the Department of Radiation Oncology.
Haas-Kogan has held a number of positions at University of California, San Francisco’s (UCSF) Helen Diller Family Comprehensive Cancer Center, most recently as program director and vice chair in the Department of Radiation Oncology at the Helen Diller Family Comprehensive Care Center and UCSF Benioff Children’s Hospital and professor of Radiation Oncology and Neurological Surgery. Previously, she was the residency program director and vice-chair for Research and Education.
She has an active laboratory-based research program that is investigating novel therapeutic agents for adult and childhood brain tumors as well as pediatric malignancies. Dr. Haas-Kogan is the principle investigator for several clinical trials, including investigator-initiated studies and cooperative group trials run by the Children’s Oncology Group and the Pacific-Pediatric Neuro-Oncology Consortium.
“Dr. Haas-Kogan brings extraordinary expertise and leadership that will greatly benefit our patients, faculty, staff and learners,” said Edward J. Benz, Jr., MD, president and CEO of Dana-Farber Cancer Institute. “Her research interests also fit well with our current efforts, and we are delighted that she will be joining us to lead such an important area of our joint cancer program.”
“A collaborative leader, Dr. Haas-Kogan brings a depth and breadth of experience in patient care, research and teaching which will enrich our radiation oncology service and benefit the patients we serve,” said Betsy Nabel, MD, president of Brigham and Women’s Health Care. “We look forward to building on the tradition of excellence in Radiation Oncology under her leadership.”
After receiving a bachelor’s degree in biochemistry and molecular biology at Harvard University, Haas-Kogan received an MD from University of California, San Francisco School of Medicine. She completed an internal medicine residency at California Pacific Medical Center and radiation oncology residency at University of California, San Francisco, where she was also chief resident and a post doctoral fellow.
Dr. Ivinson was the founding Director of the Harvard NeuroDiscovery Center—a cross-institutional research center that translates knowledge of the structure and function of the brain into an understanding of the pathogenesis of major neurological diseases and therapeutic opportunities. He helped develop the vision of an integrated and tightly managed research center engaged in groundbreaking and collaborative research at Harvard Medical School, its affiliated research hospitals, and other leading research groups around the world.
After 12 years leading the Center, Adrian stepped down as director and took the position of Director of Translational Research, allowing him to focus on those programs with a more overt translational emphasis. In January 2015, he moved to the Brigham and Women’s Hospital and added Executive Director of the Ann Romney Center for Neurologic Diseases; Executive Director of the BWH Institute for the Neurosciences; and Executive Director, Evergrande Center for Immunologic Diseases, to his responsibilities.
Prior to his appointment as HNDC Director, Adrian was Special Advisor to the Provost of Harvard University. From 1993-2000 he held a number of leadership positions at the prestigious Nature Publishing Group, including Editor-in-Chief of the journal Nature Medicine and Publisher of the Nature monthly journals. Trained as a geneticist, Dr. Ivinson’s research interests are focused on highly collaborative approaches to translational biomedical research.
Dr. Jeff Karp is an Associate Professor at Brigham and Women’s Hospital, Harvard Medical School, and is Principal Faculty at the Harvard Stem Cell Institute, an affiliate faculty at MIT through the Harvard-MIT Division of Health Sciences and Technology, and an affiliate faculty at the Broad Institute.
His research harnesses materials science and stem cell biology to solve medical problems with emphasis on nanoscale/microscale materials and bio-inspired approaches. He has published more than 100 peer-reviewed papers and book chapters and has given over 200 national and international invited lectures and has 65 issued or pending patents.
Several technologies that Dr. Karp has developed have formed the foundation for multiple products on the market and currently under development and for the launch of two companies, Gecko Biomedical and Skintifique.
Dr. Karp’s work has been recognized by CNN, NPR Science Fridays, Boston Globe, ABC News, MSNBC, Fox News, CBC Quirks and Quarks, CanadaAM, BBC, LA Times, Forbes, National Geographic, Popular Science, the Washington Post, the New York Post, and by Wired Magazine.
In 2011 the Boston Business Journal recognized Dr. Karp as a Champion in Healthcare Innovation. Two years later the Institute for Chemical Engineers (IChemE) honored one of his technologies as the Most Innovative Product of the Year. In 2008 MIT’s Technology Review Magazine (TR35) also recognized Dr. Karp as being one of the top innovators in the world under the age of 35 (3 members from his laboratory have already received this award).
He has received the Society for Biomaterials Young Investigator Award and his work has been selected as one of Popular Mechanic’s “Top 20 New Biotech Breakthroughs that Will Change Medicine.” Dr. Karp was also elected in 2013 to the American Institute for Medical and Biological Engineering’s College of Fellows and as a Kavli Fellow.
In 2014 he gave a TEDMED talk on bioinspired medical innovation and in 2015 became a member of the TEDMED Editorial Advisory Board to help curate the stage program’s themes, topics, speakers and performers. In 2015 he received a Breakthrough Award from the Kenneth Rainin Foundation and was a commencement speaker for the Faculty of Dentistry and Faculty of Pharmacy at the University of Toronto. He also recently was named to the Top 40 Under 40 business leaders by the Boston Business Journal.
An acclaimed mentor, Dr. Karp was selected as the Outstanding Faculty Undergraduate Mentor among all Faculty at MIT. He has also received the HST McMahon Mentoring award for being the top mentor among all faculty who mentor Harvard-MIT students. To date, 17 trainees from his laboratory have secured faculty positions at institutions throughout the world.
As Finance and Operations Manager of the TA, Meredith is responsible for financial planning and analysis, establishing and monitoring operational procedures, procurement, and working closely with the Director on business and strategic planning initiatives. Prior to this role, Meredith was a Senior Consultant in the Analysis and Planning group at BWH, in which she lead financial and operational analyses and business planning needs for the Senior VP of Clinical Services.
Dr. Laidlaw is an allergist, Assistant Professor of Medicine at Harvard Medical School, and Associate Physician at BWH. She is the Director of Translational Research in Allergy, and Director of the AERD (Aspirin-Exacerbated Respiratory Disease) Center at the BWH Division of Rheumatology, Immunology, and Allergy.
Dr. Calum MacRae is chief of cardiovascular medicine at Brigham and Women’s Hospital (BWH) and an expert member of BWH’s Cardiovascular Genetics Program, which comprehensively evaluates, diagnoses and manages care for inherited cardiac disorder patients. In addition, he is a leading investigator at the BWH Genomics Center and an associate professor of medicine at Harvard Medical School.
He received his medical degree from University of Edinburgh College of Medicine. He completed two internal medicine residency programs: one at Wellcome Trust Centre for Neuroimaging in London and the other at BWH. He then completed a fellowship in cardiovascular disease at Massachusetts General Hospital. Dr. MacRae is board certified in internal medicine and cardiovascular disease.
Dr. MacRae is a cardiologist and geneticist whose clinical interests include investigating new phenotypes and how research findings—including genomics discoveries—can be systematically implemented into clinical care. His research focuses on the biology and genomics of cardiovascular disease, specifically the biological basis of different arrhythmia susceptibilities. He holds five patents, has authored over 160 peer-reviewed publications and received research funding from the National Institutes of Health’s National Human Genome Research Institute.
Terry is the Assistant Vice President, Institutional Research in the Development Office at Brigham and Women’s Hospital. He is an experienced healthcare fundraising professional with proven track record at world-class academic healthcare institutions including BWH and the Dana-Farber Cancer Institute.
As a senior resource development officer for cross disciplinary research efforts, works closely with major donors and hospital leadership on key research and capital campaign initiatives. Philanthropically launched several collaborative research centers and programs including the Reny Stepping Strong Center for Trauma Innovation, Engels TSC/LAM Research Program, Dagres Neuropsychiatric Translational Research Suite, Smith Rheumatology Research Program, Simboli Severe Asthma Research Program, BWH “Shark Tank” Technology and Innovation Awards Program, and Partner’s Impact Investing Venture Capital Fund
Recipient of the Partners Healthcare Partners in Excellence Award (2014) and the Association of American Medical Colleges Award for Excellence (2016)
Allison Moriarty, MPH is the Vice President of Research Administration and Compliance at BWH. She oversees compliance and ensures that all endeavors meet or exceed federal, state, and local regulations and other policy requirements. She is also responsible for oversight of research operations at BWH and BWFH, including building and maintaining the necessary infrastructure and resources to support the institutions’ research goals.
Allison co-chairs the TA Advisory Team.
Emily Natale, MA, LMHC, AT actively manages and facilitates all project goals, priorities and milestones, ensuring projects are delivered in a timely and efficient manner. Using clear communication and a sincere commitment to projects, Emily works collaboratively with different affiliated offices, as well as external collaborators, to help analyze problems, design creative solutions and provide proper project follow-up.
Emily Natale is a licensed mental health counselor (LMHC) and expressive art therapy clinician (AT) by training. She obtained her B.S. in Psychology and Art Therapy, and her M.A. in Expressive Art Therapy and Mental Health Counseling from Lesley University in Cambridge, MA. Prior to this role, Emily worked as a clinician, focusing on children and families impacted by psychological trauma. Additionally, she worked as an assistant program manager for a behavioral health crisis-outreach program, overseeing 35+ staff. Furthermore, Emily has 17+ years of hospitality experience, including roles in managerial hospitality. Emily’s background in psychology, management, hospitality and art, aid in her ability to build strong collaborations and assist in the achievement of deliverables, milestones, and project closure.
Dr. Paul M. Ridker is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital (BWH). A cardiovascular medicine specialist, he is also the Eugene Braunwald Professor of Medicine at Harvard School of Medicine (HMS).
Dr. Ridker received his medical degree from HMS. He then completed an internal medicine residency and a cardiology fellowship at BWH. Dr. Ridker is board certified in internal medicine. He provides outpatient services at the Southern Jamaica Plain Health Center, a public-health clinic affiliated with BWH and HMS. His clinical interests include coronary artery disease and the underlying causes and prevention of atherosclerotic disease.
Dr. Ridker is the author of over 500 peer-reviewed publications, 150 reviews and book chapters, and five textbooks related to cardiovascular medicine. Dr. Ridker’s primary research focus has involved inflammatory mediators of heart disease and the molecular and genetic epidemiology of hemostasis and thrombosis, with particular interests in biomarkers for coronary disease, “predictive” medicine, and the underlying causes and prevention of atherosclerotic disease. Between the years 2000 and 2010, he was among the 10 most often cited researchers in cardiovascular medicine worldwide. Dr. Ridker been listed as one of America’s Top Doctors by Castle Connolly and named a top cardiologist by Boston Magazine.
Dr. Sang is a pain specialist and anesthesiologist whose clinical lab conducts important research into novel analgesics to target specific mechanisms of pain.
She received her medical degree from Johns Hopkins University in Baltimore, and also earned a Master of Public Health from Harvard University. After completing her internship in pediatrics at Children’s Hospital of Philadelphia, and a residency in anesthesiology at Johns Hopkins Hospital, she continued her medical training at Harvard Medical School and the National Institutes of Health in Bethesda, Maryland. At the National Institutes of Health Clinical Center, she was the Associate Medical Director of the Pain Research Clinic. Prior to heading the Translational Pain Research Program at the Brigham and Women’s Hospital, Dr. Sang served as the Director of the Clinical Trials Program at the Massachusetts General Hospital Pain Center.
Dr. Sang serves on the Board of Directors of the American Pain Society, and is a founding member and steering committee member of the Neuropathic Pain Institute. She has been selected as a member of numerous national and international steering committees and scientific advisory boards for professional societies and pharmaceutical companies. In addition, she has organized and participated in consensus conferences in neuropathic pain, neurofibromatosis, and spinal cord injury.
Dr. Sang’s clinical lab is funded by competitive private sources, including the Paralyzed Veterans of America and the Christopher Reeve Paralysis Foundation, as well as the National Institutes of Health. In addition to the research conducted in her own lab, Dr. Sang is an active consultant in the discovery and clinical development of novel analgesics, clinical trial design, and pain management of central and peripheral neuropathic syndromes.
Dr. Schoen is the Executive Vice Chairman of BWH’s Department of Pathology, and Professor of Pathology and Health Sciences and Technology at Harvard Medical School. He investigates the functional structure and cell/matrix biology, and tissue engineering of heart valves. The objectives of these studies are to understand the mechanisms of normal valve functional dynamics and how these are disrupted in valve disease, and the limitations to the success of currently available prosthetic devices. His studies provide input to the development of improved management strategies for native and prosthetic valve disease and potentially new medical devices.
Dr. Selkoe is the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School, and Co-Director, Center for Neurological Diseases, Department of Neurology, BWH. He has devoted his career to the use of molecular approaches to study Alzheimer’s disease, Parkinson’s disease, and related basic biological questions.
Dr. Khalid Shah is an Associate Professor at Harvard Medical School and heads the Molecular Neurotherapy and Imaging Laboratory at Massachusetts General Hospital (MGH) in Boston, MA. He is also the Director of the Stem Cell Therapeutics and Imaging program at MGH and a Principal Faculty at Harvard Stem Cell Institute in Boston.
In recent years, Dr. Shah and his team have pioneered major developments in the cancer research field, successfully developing therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, JNCI, Stem Cells, Lancet Oncology and Nature Reviews Cancer. The potential of developing novel cancer therapies in his laboratory has been recognized by many cancer alliances and associations. Based on this, he has received the young investigator award from ACGT, Research fellow award from ACS, Innovation awards from James McDonnell Foundation, ABTA, Goldhirsh foundation and American Association of Radiology. Recently, Dr. Shah’s work has been highlighted in the media world-wide including features on BBC and CNN. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of stem cell therapy and oncology. The technologies from Dr. Shah’s laboratory have led to the foundation of a biotech company, AMASA Technologies Inc. whose main objective is the clinical translation of therapeutic stem cells in cancer patients.
Dr. Shah has participated in the training of numerous undergraduate, graduate students and residents at MGH and the potential of his mentoring has been recognized by Harvard Medical School, who awarded him the Harvard Young Mentor Award. Dr. Shah has also launched an outreach program to create public awareness of the fervent need for effective cancer treatments, and the current research on the cusp of clinical translation that would yield paramount progress for cancer patients.
Dr. Jacqueline M. Slavik is the executive director of the Brigham Research Institute (BRI) at Brigham and Women’s Hospital. In this role she shapes and implements the BRI’s overarching mission to accelerate discoveries that improve human health by fostering groundbreaking, interdepartmental, and interdisciplinary research, ranging from basic fundamental studies to clinical innovations. She manages a team who works to provide a clear voice for the entire BWH research community, raise the profile of research at BWH, develop mission-centric collaborations with external entities and engage the scientific community in fundraising. Dr. Slavik received her PhD in Immunology from Harvard University, a Master of Medical Science from Harvard University and a BS in Biology from State University of New York at Albany. Dr. Slavik did her postdoctoral fellowship in the Center for Neurologic Diseases in the Department of Neurology at BWH, and held a faculty appointment as instructor in Neurology at Harvard Medical School prior to transitioning to the role of senior program manager at the BRI, from which she moved into her current leadership role. Her research interests include T lymphocytes and T lymphocyte signaling and their involvement in cancer and autoimmune diseases such as multiple sclerosis.
Dr. David Silbersweig is a neurologist and psychiatrist, and serves as the Chairman of the Department of Psychiatry at the Brigham and Women’s Hospital, and Co-Director of the Brigham and Women’s Hospital Institute for the Neurosciences. He is Harvard Medical School Dean for Academic Programs at Partners HealthCare and the Stanley Cobb Professor of Psychiatry at Harvard Medical School.
Dr. Silbersweig is one of the pioneers of functional neuroimaging research in psychiatry. He and his colleagues focus upon the development and application of new neuroimaging techniques to localize and characterize brain circuitry dysfunction underlying major psychiatric disorders. Studies combining neuroimaging with therapeutic, fluid biomarker, and genetic studies, to test mechanistic hypotheses, are underway. The aim of Dr. Silbersweig’s systems-level neuropathophysiology work is to help provide a foundation for the development of novel, targeted, biologically based diagnostic and therapeutic strategies to aid those suffering with mental illness.
Dr. Silbersweig has significant involvement in national/international research consortia. He is a Fellow of the American Neuropsychiatric Association, and has played a notable role in shaping the rapidly developing field of neuropsychiatry through his translational research, his innovative educational activities, his invited presentations in the United States and abroad, and his work with scientific journals, NIH, conferences and organizations.
Lesley Solomon’s passion for innovation was fostered out of her many experiences at start ups creating new revenue models, building brands and growing high-impact teams. As the Executive Director of the Brigham and Women’s Hospital Innovation Hub she is now responsible for leading a team working with clinicians and scientists to help them realize their dreams of transforming ideas into innovations to impact patient care.
Lesley is also the Director of Strategy and Innovation in the Brigham Research Institute, leading the hospital’s effort in deepening its relationship with the biotechnology and pharmaceutical industries to accelerate science from bench to bedside. In both roles Lesley works closely with the start up community as well as established industry to form collaborations in the pursuit of improving patient care.
She brings forth 20+ years of experience as an executive working in business development, strategy, and marketing at start ups, early stage, and large companies such as the Food Network, Barnes & Noble.com, and Yoga Works. Lesley received her MBA from Harvard Business School and has a B.A. in English from Cornell University.
Lesley sits on the board of Primary Care Progress and is a founding member of WomenAgainstAlzheimer’s. She lives in Brookline, MA with her husband Derek and her two boys.
Dr. Scott D. Solomon serves as director of Noninvasive Cardiology and co-director of the Cardiac MRI Program at Brigham and Women’s Hospital (BWH). He is also the director of the BWH Cardiovascular Imaging Core Laboratory and Clinical Trials Endpoints Center. He is a professor in medicine at Harvard Medical School (HMS).
He received his medical degree from HMS. He completed an internal medicine residency and a cardiovascular medicine fellowship at BWH. Dr. Solomon is board certified in internal medicine and cardiovascular disease.
Dr. Solomon’s clinical interests include echocardiography, stable heart failure and risk modification for myocardial infarction patients. His research focuses on changes in ventricular structure and function following myocardial infarction, modifiers of risk and influences of outcomes in patients following myocardial infarction and chronic heart failure.
Dr. Weiner is the Robert L. Kroc Professor of Neurology at Harvard Medical School, Founder and Director of the Partners Multiple Sclerosis Center, and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s. Vaccines based on his work are being tested in multiple sclerosis, diabetes, and most recently in Alzheimer’s disease.
As Director of the TA, Dr Williamson is responsible for all operational aspects, including designing and executing the business plan and strategy. Lina holds more than 12 years of experience in the Pharmaceutical and Biotechnology Industries in areas ranging from Research, Business Development, Strategic Alliances, Scientific Operations, and Entrepreneurship & Innovation. She also serves as Innovation Strategist for the Brigham Research Institute (BRI).